-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

CD19 Antibodies and CD79-Directed ADCs in B-cell Malignancies

Program: Scientific Workshops @ ASH
Session: Immune Engaging Molecules in the Management of Lymphoid Malignancies
Wednesday, December 2, 2020, 7:05 AM-8:20 AM

Laurie H. Sehn, MD, MPH

Centre for Lymphoid Cancer, Department of Medical Oncology, BC Cancer and The University of British Columbia, Vancouver, BC, Canada

Disclosures: Sehn: Amgen: Consultancy, Honoraria; AbbVie: Consultancy, Honoraria; Verastem Oncology: Consultancy, Honoraria; Celgene: Consultancy, Honoraria; Acerta: Consultancy, Honoraria; Janssen: Consultancy, Honoraria; Incyte: Consultancy, Honoraria; Seattle Genetics: Consultancy, Honoraria; MorphoSys: Consultancy, Honoraria; F. Hoffmann-La Roche Ltd: Consultancy, Honoraria, Research Funding; Chugai: Consultancy, Honoraria; TG therapeutics: Consultancy, Honoraria; Lundbeck: Consultancy, Honoraria; Karyopharm: Consultancy, Honoraria; Teva: Consultancy, Honoraria, Research Funding; Servier: Consultancy, Honoraria; Takeda: Consultancy, Honoraria; Gilead: Consultancy, Honoraria; Kite: Consultancy, Honoraria; Apobiologix: Consultancy, Honoraria; Merck: Consultancy, Honoraria; AstraZeneca: Consultancy, Honoraria; Genentech, Inc.: Consultancy, Honoraria, Research Funding.

See more of: Immune Engaging Molecules in the Management of Lymphoid Malignancies
See more of: Scientific Workshops @ ASH
<< Previous Presentation | Next Presentation >>